**Original Article**

**AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation**

Ji-Ming Bao¹²*, Min-Yi He³*, Ya-Wei Liu⁴, Yong-Jie Lu⁵, Ying-Qia Hong⁶, Hai-Hua Luo², Zhong-Lu Ren⁷, Shan-Chao Zhao¹, Yong Jiang²

¹Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; ²Key Laboratory of Proteomics of Guangdong Province and Key Laboratory of Transcriptomics and Proteomics of Human Diseases Supported by The Ministry of Education of China, Southern Medical University, Guangzhou 510515, China; ³Department of Organ Transplantation, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China; ³Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; ²Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; ⁴Department of General Surgery, Affiliated Chaozhou Central Hospital of Southern Medical University, Chaozhou 521021, China; ⁵Department of Bioinformatics, School of Basic Medical Sciences, Southern Medical University, Guangzhou510515, China. *Equal contributors.

Received February 16, 2015; Accepted April 12, 2015; Epub April 15, 2015; Published May 1, 2015

**Abstract:** Metabolomic research has revealed that metabolites play an important role in prostate cancer development and progression. Previous studies have suggested that prostate cancer cell proliferation is induced by advanced glycation end products (AGEs) exposure, but the mechanism of this induction remains unknown. This study investigated the molecular mechanisms underlying the proliferative response of prostate cancer cell to the interaction of AGEs and the receptor for advanced glycation end products (RAGE). To investigate this mechanism, we used Western blotting to evaluate the responses of the retinoblastoma (Rb), p-Rb and PI3K/Akt pathway to AGEs stimulation. We also examined the effect of knocking down Rb and blocking the PI3K/Akt signaling pathway on AGEs induced PC-3 cell proliferation. Our results indicated that AGE-RAGE interaction enhanced Rb phosphorylation and subsequently decreased total Rb levels. Bioinformatics analysis further indicated a negative correlation between RAGE and RB1 expression in prostate cancer tissue. Furthermore, we observed that AGEs stimulation activated the PI3K/Akt signaling pathway and that blocking PI3K/Akt signaling abrogated AGEs-induced cell proliferation. We report, for the first time, that AGE-RAGE interaction enhances prostate cancer cell proliferation by phosphorylation of Rb via the PI3K/Akt signaling pathway.

**Keywords:** AGEs, RAGE, prostate cancer, proliferation, retinoblastoma, Akt

**Introduction**

Recent metabolomics studies have reported that human metabolites play important roles in prostate cancer development and progression. Advanced glycation end products (AGEs) are non-enzymatic protein modifications that are produced during the normal aging process [1]. The major AGEs receptor, the receptor for advanced glycation end products (RAGE, also called AGER) [2], is overexpressed in a variety of tumor types including prostate cancer [3, 4]. It has been suggested that AGE-RAGE interaction is involved in the development, growth and metastasis of a number of tumor types [5-7], including prostate cancer [3]. However, the AGE-RAGE related molecular mechanisms regulating these effects in prostate cancer cell remain unclear.

Previous studies have suggested that AGEs stimulation significantly increases the number of cells in the S phase of the cell cycle and decreases the percentage of cells in G1 phase [5]. Furthermore, it has been demonstrated that RAGE knockdown induces cell cycle arrest in the G1 phase [8, 9]. Therefore, it is likely that AGE-RAGE interaction affects cell cycle genes controlling the G1/S phase transition.

The retinoblastoma (Rb)/E2F pathway plays a key role in cell cycle progression and proliferation [10]. Rb is an important regulator of the G1
AGE/RAGE/Akt promotes prostate cancer proliferation

AGE/RAGE/Akt promotes prostate cancer proliferation

Figure 1. AGEs stimulation methods. PC-3 cells were plated in petri dishes in complete medium for 24 h, and then the medium was changed to FBS free medium for 24 h before stimulation. For concentration gradient stimulation, cells were treated with 0 μg/ml, 1 μg/ml, 10 μg/ml, 100 μg/ml, 200 μg/ml or 400 μg/ml for 48 h. For the time course treatment, cells were treated with 200 μg/ml for 48 h, 36 h, 24 h, 12 h, 6 h and 0 h.

Materials and methods

Cell culture and treatment

PC-3 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and phenol red (GIBCO, Life Technologies, Grand Island, NY, USA), containing L-glutamine (2 mM) (Invitrogen, Life Technologies) and penicillin sodium (100 U/ml)/streptomycin sulfate (100 mg/ml) (Invitrogen) in a humidified incubator at 37°C with 5% CO₂.

PC-3 cells were cultured in 60-mm dishes or 96 well plates for 24 h. After 24 h, the medium was changed to FBS-free MEM, and then cells were incubated for another 24 h before stimulation with AGEs (BioVision, San Francisco, CA, USA). Cells were treated for 48 h with a concentration gradient of AGEs (0 μg/ml, 1 μg/ml, 10 μg/ml, 100 μg/ml, 200 μg/ml, 400 μg/ml); or with 200 μg/ml for various durations (48 h, 36 h, 24 h, 12 h, 6 h and 0 h; Figure 1). Total RNA or cell lysates were extracted and analyzed in each experiment.

CCK-8 cell proliferation assay

PC-3 proliferation was evaluated using the CCK-8 assay according to the manufacturer’s instructions (Dojindo, Kumamoto, Japan). Cells were cultured in FBS medium as described above at 3 × 10³ cells per well (n = 5) in 96-multiwell plates, and then 10 μl CCK-8 (5 mg/ml) was added to each well. After 4 h incubation at 37°C, the optical density (OD) of each well was measured using a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 450 nm. Each experiment was repeated three times.

Bioinformatics analysis of RAGE and RB1 expression in prostate cancer

RAGE and RB1 expression in prostate cancer was analyzed by bioinformatics. All data were downloaded from The Cancer Genome Atlas (TCGA) database (http://cancergenome.nih.gov/), and all data used were TCGA data level 3 (Segmented or Interpreted Data). Three-hundred and eighty-three of the prostate cancer samples in the data set were prostate adenocarcinoma (PRAD). All gene quantification was done by RNA-seq on an Illumina HiSeq_RNASeqV2 platform (Illumina, San Diego, CA, USA) and RSEM normalization (http://dewey-
AGE/RAGE/Akt promotes prostate cancer proliferation

Protein extraction and Western blotting

Protein expression levels were assessed by Western blotting analysis. In brief, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer containing 1 × PBS, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 5 mM EDTA, 0.5% sodium deoxycholate, 1 mM sodium orthovanadate and protease inhibitors. Protein concentration was quantified and an equal amount of protein was loaded in each well of an SDS-PAGE gel. Next, select targets were detected using the following antibodies: RAGE, primary anti-RAGE antibody (CST 4679, 1:2000; Cell Signaling Technology (CST), Danvers, MA, USA); Rb, anti-Rb antibody (CST 9309, 1:2000; CST); phospho(p)-Rb (Ser807/811), anti-p-Rb antibody (CST 8516, 1:1000; CST); Akt, primary anti-Akt antibody (CST 4691, 1:1000; CST); phospho(p)-Akt (Ser473), primary anti-p-Akt (Ser473) antibody (CST 9309, 1:2000; CST); phospho(p)-Akt (Thr308), primary anti-p-Akt (Thr308) antibody (CST 4060, 1:1000; CST); β-actin, Rabbit anti-β-actin (1:500; Santa Cruz, CA) antibody. β-actin served as an internal control.

Ly294002 blockade of PI3K/Akt signaling pathway

Ly294002 (CST 9901, CST), a highly selective PI3K inhibitor, was used to block PI3K-dependent Akt phosphorylation and, thus, the PI3K/Akt signaling pathway. Prostate cancer cells were treated with 20 nmol/ml Ly294002 for 24 h, then p-Akt (Ser473), p-Akt (Thr308) and total Akt were measured using Western blotting to confirm blockage of the PI3K/Akt signaling pathway.

### Table 1. Primers and siRNA Sequences

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence</th>
<th>Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>5'-TGCCACCACTTCTCAGAATG-3' (forward)</td>
<td>For qRT-PCR</td>
</tr>
<tr>
<td></td>
<td>5'-TCTGACTATGCTGGGTACCT-3' (reverse)</td>
<td></td>
</tr>
<tr>
<td>RAGE</td>
<td>5'-AAACATCACGGCAGGATTG-3' (forward)</td>
<td>For qRT-PCR</td>
</tr>
<tr>
<td></td>
<td>5'-TCGGCCCTGTTCTCTTTCT-3' (reverse)</td>
<td></td>
</tr>
<tr>
<td>RB</td>
<td>5'-GAGATGATGTCACCAGGG-3' (forward)</td>
<td>For qRT-PCR</td>
</tr>
<tr>
<td></td>
<td>5'-AACGGTTCACCAGGAGAATGAG-3' (reverse)</td>
<td></td>
</tr>
<tr>
<td>siRAGE</td>
<td>5'-CCACCUUCUGCUUAGCUGUUTT-3'</td>
<td>For RNAi</td>
</tr>
<tr>
<td></td>
<td>5'-AACGACAGGAGAAGUGGTT-3'</td>
<td></td>
</tr>
<tr>
<td>siRB</td>
<td>5'-GGCCCCAGAUAGCGAAGUTT-3'</td>
<td>For RNAi</td>
</tr>
<tr>
<td></td>
<td>5'-ACUUCUGCUAUAUUGGCGCTT-3'</td>
<td></td>
</tr>
<tr>
<td>siNC</td>
<td>5'-UCUCUGACCGUUCUGAATT-3'</td>
<td>For RNAi</td>
</tr>
</tbody>
</table>

Lab.biostat.wisc.edu/rsem). Normalized readings represented the gene expression level.

Data analysis was done in the R language environment. The correlation between RB1 and RAGE was obtained by Pearson correlation and the significance of correlation result was confirmed with a correlation test. Finally, data was visualized using a scatter plot in which the horizontal axis represents RB1 quantification, the vertical axis represents RAGE quantification, and a blue line represents the linear regression line.

RAGE and RB1 knockdown using RNA interference (RNAi)

The target small interfering RNA (siRNA) for RAGE (siRAGE), RB1 (siRB) and negative-control siRNA (siNC) were purchased from GenePharma (Shanghai, China). siNC consisted of an irrelevant sequence. Table 1 lists the siRNA sequences used. Exponentially growing cells were plated in 6 cm or 96-well plates at 30 to 50% confluence, and then incubated for 24 h. After incubation, cells were transfected with small RNAs in serum free medium OPTI-MEM-I (Invitrogen) according to the manufacturer’s protocol. Gene knockdown efficacy was evaluated using Western blot and Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) analysis.

qRT-PCR analysis for gene expression

RAGE, RB1 and β-actin primers were purchased from Invitrogen. Total cell RNA was extracted using Trizol (Invitrogen) following the manufacturer’s instructions. Mature mRNA quantification was performed using the Quantitect SYBR Green PCR Kit (Stratagene, La Jolla, CA, USA) and the MX3005P multiplex quantitative PCR system (Stratagene) according to the manufacturers’ recommendations. β-actin mRNA was chosen as a housekeeping gene. Relative mRNA expression was calculated using the comparative CT (ΔΔCT) method as previously described [23, 24]. Fold-changes were calculated by the equation $2^{-ΔΔCT}$. All primers used are listed in Table 1.
AGE/RAGE/Akt promotes prostate cancer proliferation

Statistical analysis

All data are presented as means ± SD. When the variance was homogeneous, one-way ANOVA was applied to analyze the differences between groups and least significant difference (LSD) tests were used to compare the means of two groups. When the variance was heterogeneous, Welch’s t test was applied to analyze the differences between each groups and Dunnett’s T3 test was used to compare the means of two groups. \( p < 0.05 \) was considered as statistically significant (two-tailed).

Results

AGEs induce prostate cancer cell proliferation via AGE-RAGE interaction

PC-3 cells were stimulated for 48 h with AGEs in a gradient concentration. Cell viability improved significantly with increasing AGEs concentrations (Figure 2A). When the cells were stimulated with increasing durations of 200 μg/ml AGEs, cell proliferation increased along with the increasing duration of AGEs exposure (Figure 2B).

Figure 2. The effects of AGE-RAGE interaction on PC-3 cell proliferation. (A) PC-3 cells were stimulated with AGEs in a gradient concentration for 48 h, and then cell proliferation was evaluated by the CCK-8. AGEs (≥ 100 μg/ml) stimulation promoted cell proliferation when compared with the no treatment (0 μg/ml) group (*\( p < 0.05 \)). (B) PC-3 cells were treated with a time course of 200 μg/ml AGEs, and then cell proliferation was evaluated by the CCK-8. More than twenty-four h 200 μg/ml AGEs stimulation promoted cell proliferation when compared with the no treatment (0 h) group (*\( p < 0.05 \)). (C) RAGE expression was detected by qRT-PCR analysis after the cells were transfected with siRNA. siRAGE significantly knocked the expression of RAGE down when compared with siNC (*\( p < 0.01 \)). (D) RAGE expression was detected by Western blot after the cells were transfected with siRNA. siRAGE significantly knocked the expression of RAGE down when compared with siNC. (E) PC-3 cells were treated with or without AGEs after siRAGE or siNC transfection, and then cell proliferation was determined by CCK-8 assay. The OD value of the siNC + AGEs group was higher than the siNC group (*\( p < 0.01 \)). The OD value of the siRAGE + AGEs group was lower than the siNC + AGEs group (*\( p < 0.01 \)).
To investigate whether AGEs exposure required RAGE to enhance PC-3 proliferation, an RNAi knockdown of RAGE expression was performed. After RAGE siRNA transfection, Western blotting and qRT-PCR were used to evaluate gene silencing efficiency. After examining both RAGE mRNA and protein levels, we observed that the RAGE siRNA knockdown was successful (Figure 2C and 2D, p < 0.01). Next, PC-3 cells, with or without RAGE knockdown, were stimulated with 200 μg/ml AGEs for 48 h. CCK-8 assays demonstrated that RAGE siRNA pretreatment abrogated AGE-induced proliferation (Figure 2E, p < 0.01). These results suggested that the proliferation-promoting activity of AGEs was mediated by AGE-RAGE interaction.

**RAGE and RB1 gene expression in prostate cancer samples**

Data from 383 prostate cancer tissue samples were collected for bioinformatics analysis. Correlation tests indicated a highly significant negative correlation between RAGE and RB1 expression (p < 2.2e-16). A similar correlation was also seen between RAGE and RB1 in prostate cancer samples by linear regression analysis (p < 2e-16, Figure 3A).

**Continued AGEs stimulation promoted phosphorylation and decreased levels of Rb**

To confirm the correlation between AGE-RAGE and Rb, we detected total and phosphorylated
Rb levels after AGES stimulation by Western blot. The results showed increased p-Rb, but decreased total Rb levels. This response occurred in a time and AGES concentration dependent manner (Figure 3B and 3C).

**AGE-RAGE interaction enhanced prostate cancer cell proliferation by regulating Rb**

We next confirmed that AGE-RAGE regulation of Rb promoted prostate cancer cell proliferation. Rb expression was inhibited using RNAi, and then cell proliferation was measured using the CCK-8 cell viability assay. Western blotting and qRT-PCR analysis indicated that Rb mRNA and protein levels were both significantly decreased by Rb RNAi treatment (Figure 4A and 4B). CCK-8 assays demonstrated that the PC-3 cell proliferation rates of the siNC + AGES, siRB and siRB + AGES treated cells were significantly higher than the proliferation rate of siNC treated cells (p < 0.05). However, no significant proliferation differences were observed between siNC + AGES, siRB or siRB + AGES treated PC-3 cells (p > 0.05; Figure 4C). Both AGES stimulation and Rb silencing induced PC-3 cell proliferation, but cell proliferation was not further elevated by AGE-induced stimulation after Rb silencing. Thus, these results indicated that AGE-RAGE induces cancer cell proliferation by regulating Rb.

**PI3K/Akt signaling pathway activation was required for AGES induced PC-3 proliferation**

To analyze the role of the Akt pathway in AGES/Rb mediated PC-3 cell proliferation, we examined Akt phosphorylation status. The results showed increased Akt (Ser473) phosphorylation in response to AGES treatment in a time and concentration dependent manner. However, the phosphorylation of Akt (Thr308) showed no significant response to treatment (Figure 5A and 5B). These results indicated that the PI3K/Akt signaling pathway was activated by AGES treatment.

To confirm PI3K/Akt signaling pathway involvement in AGES/Rb mediated PC-3 cell proliferation, Ly294002 was used to block Akt phosphorylation and the PI3K/Akt signaling pathway. Twenty-four h after Ly294002 treatment, p-Akt (Ser473), p-Akt (Thr308) and total Akt were detected using Western blotting. Both p-Akt (Ser473) and p-Akt (Thr308) decreased dramatically, indicating the successful blockade of the PI3K/Akt signaling pathway (Figure 5C). A subsequent CCK-8 assay showed that 48 h of AGES stimulation could not promote PC-3 cell proliferation when the PI3K/Akt signaling pathway was blocked by Ly294002 pretreatment (Figure 5D).
Discussion

Epidemiologic studies have suggested that diabetes is associated with an increased risk of prostate cancer recurrence [25, 26] and cancer-related mortality [27, 28]. The production and accumulation of AGEs are accelerated in diabetes [29], indicating the possibility of a link between diabetes, increased prostate cancer risk and AGEs accumulation. In our earlier work, we observed that RAGE expression was associated with prostate cancer progression and poor patient outcome [30]. The study we report here confirmed that AGEs treatment stimulated prostate cancer cell proliferation in a dose- and time-dependent manner. Furthermore, this observation is supported by other studies [3, 5, 31]. However, the mechanism remained unknown. Here, we suggest a role for the Akt/Rb pathway in AGEs induction of prostate cancer cell proliferation.

We demonstrated that AGE-RAGE interaction promoted prostate cancer cell proliferation by inducing the phosphorylation and subsequent degradation of Rb. This result established, for the first time, an association between AGE-RAGE and Rb. During prostate cancer progression, tumor cells undergo a variety of molecular alterations that lead to the acquisition of uncontrolled growth properties. Rb is a key cell cycle inhibitor and tumor suppressor. The unphosphorylated, active form of Rb interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest [32]. Hyperphosphorylation of RB by the cyclin-dependent kinases 4 and 6 (CDK4/6) leads to the dissociation of the Rb-E2F complex and proteasome degradation of Rb via a ubiquitin-dependent pathway [32]. The release of E2F from the Rb-E2F complex triggers the activation of a number of genes required for G1/S transition and tumorigenesis [33]. Therefore, it is highly possible that AGE-RAGE interaction in prostate cancer cell induces Rb phosphorylation, the resultant dissociation of the Rb-E2F complex, the subsequent degradation of Rb through the ubiquitin-proteasome complex and, finally, the

Figure 5. The effect of the PI3K/Akt signaling pathway on AGEs induced PC-3 proliferation. (A) The phosphorylation status of Akt after stimulation with an AGEs concentration gradient. PC-3 cells were treated with an AGEs concentration gradient for 48 h, p-Akt (Ser473), p-Akt (Thr308) and total Akt were detected by Western blot. (B) The phosphorylation status of Akt after increasing durations of AGEs stimulation. PC-3 cells were treated with 200 μg/ml AGEs for increasing periods of time, and then Western blotting was used to detect p-Akt (Ser473), p-Akt (Thr308) and total Akt. (C) Ly294002 blocked p-Akt (Ser473) and p-Akt (Thr308) phosphorylation. Cells were treated with Ly294002 for 24 h, and then p-Akt (Ser473), p-Akt (Thr308) and total Akt were detected with Western blotting. (D) The proliferation of PC-3 cells was significantly inhibited after Ly294002 pretreatment to block the PI3K/Akt pathway. Cells were treated with or without AGEs after Ly294002 pretreatment or without Ly294002 pretreatment, and then cell proliferation was evaluated by CCK-8 assay. The OD value of the AGEs treatment group was higher than the no AGEs control group (*p < 0.05). The OD value of the AGEs treatment (without Ly294002) group was higher than the Ly294002 pretreatment + AGEs treatment group (**p < 0.01).
AGE/RAGE/Akt promotes prostate cancer proliferation

The promotion of cancer cell proliferation by allowing cell cycle progression from the G1 to the S-phase. Additionally, bioinformatics analysis of a large number of prostate cancer samples from the TCGA database also indicated a significant negative correlation between the expression quantification of RAGE and RB1 genes.

To investigate the mechanisms underlying AGE-RAGE regulation of Rb, we analyzed related signaling pathways. Many previous studies in various cell types have explored the signaling pathways mediated by RAGE, including the MAPK [34], JAK/STAT [35] and NF-κB [36] pathways; however, the involvement of RAGE related signaling pathways has not been frequently reported in prostate cancer. Here, we observed that AGE-RAGE interaction activated the PI3K/Akt signaling pathway by increasing Akt (Ser473) phosphorylation. This observation is consistent with previous studies reported that activation of the PI3K/Akt pathway could be mediated by the interactions between RAGE and its ligands [5, 37-39]. The PI3K/Akt signaling pathway has been shown to be essential for the survival of a number of cell types and some forms of human cancer [40, 41]. Furthermore, evidence indicates that PI3K/Akt signaling may be critical for prostate cancer cell survival and proliferation and it is possible that AGE-RAGE interaction regulates Rb through the PI3K/Akt signaling pathway. This evidence suggests that Rb degradation by the PI3K/Akt/Rb signaling pathway may play a key role in AGES induced prostate cancer development.

Conclusion

This study indicates that the interaction of AGES with RAGE enhances prostate cancer cell proliferation by inducing Rb phosphorylation via the PI3K/Akt signaling pathway (Figure 6). Therefore, inhibiting the formation of AGES or RAGE downstream signaling is a promising and novel therapeutic strategy for the prevention and treatment of prostate cancer.

Acknowledgements

This study was supported by four grants from the National Natural Science Foundation of China (No. 81072092, No. 81328017, No. 813-72030 and No. 81302229), two grants from the Guangdong Provincial Science and Technology Projects of China (2012B031800302 and 2013B051000050) and two grants from President Foundation of Nanfang Hospital, Southern Medical University (G2011014 and 2013Z011).
Disclosure of conflict of interest

None.

Address correspondence to: Shan-Chao Zhao, Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. E-mail: zhaozhanchoaosmu@sina.cn; Yong Jiang, Key Laboratory of Proteomics of Guangdong Province and Key Laboratory of Transcriptomics and Proteomics of Human Diseases Supported by The Ministry of Education of China, Southern Medical University, Guangzhou 510515, China. E-mail: jiang48231@163.com

References

AGE/RAGE/Akt promotes prostate cancer proliferation


